title: Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
abstract: This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
authors: Haematology and Microbiology Institutes, Catholic University, Rome, Italy. lpagano@rm.unicatt.it
authors: L
authors: L
authors: Pagano
authors: L
authors: L
authors: Fianchi
authors: R
authors: R
authors: Fanci
authors: A
authors: A
authors: Candoni
authors: M
authors: M
authors: Caira
authors: B
authors: B
authors: Posteraro
authors: M
authors: M
authors: Morselli
authors: C G
authors: CG
authors: Valentini
authors: G
authors: G
authors: Farina
authors: M E
authors: ME
authors: Mitra
authors: M
authors: M
authors: Offidani
authors: M
authors: M
authors: Sanguinetti
authors: M E
authors: ME
authors: Tosti
authors: A
authors: A
authors: Nosari
authors: G
authors: G
authors: Leone
authors: P
authors: P
authors: Viale
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy* / Q000401:mortality; D000077336:Caspofungin; D064420:Drug-Related Side Effects and Adverse Reactions; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D016469:Fungemia / Q000188:drug therapy* / Q000401:mortality; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications*; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin